Support Project for the Finlay Institute of Vaccines (FIV) for the Production of Meningitis Vaccines
Technical Assistance
The project, implemented in partnership with AFD and KfW, aims to improve the quality standards of Cuba's Finlay Vaccine Institute (FVI) production and increase its production capacities, including vaccines against meningitis (meningococcal and pneumococcal) with a focus on the carbon footprint of vaccines manufacturing.
This action improves the number, availability and accessibility of FVI vaccines to meet national demand, but also the needs of low and middle-income countries in Latin America and the Caribbean and third regions, notably via multilateral channels as WHO, PAHO and UNICEF, thus strengthening Cuban and Latin America health security in order to limit the impact of future major health crisis.
The project also contributes to the modernization of the biotechnology sector to increase liquidities in foreign currency and support investment in Cuba to secure economic growth and foster decent employment opportunities for the Cuban population. This support will also participate to the ability of the Cuban biotechnology industry to better integrate in global initiatives and to enter into partnership with European companies.
The project's main goal is to provide health products for global health purposes where global demand exceeds available production and ensure that in case of future global epidemics there will be available production capacities to quickly respond. Some of the main results expected are:
- Finlay Vaccine Institute will produce 2 new vaccines
- Finlay Vaccine Institute will perform 5 clinical trials
- Finlay Vaccine Institute will produce 50 million doses of vaccines by 2030
- 250 qualified jobs will be created in the Cuban biotechnology sector
- 33 new female workers will be hired at Finlay Vaccine Institute, that is, 65% of the newly recruited staff
- 100 Finlay Vaccine Institute employees will receive training (50 existing and 50 newly recruited staff)
